MOTS-c and Humanin: Mitochondrial Peptides Explained

Introduction

For most of modern biology, mitochondria were taught as one thing: the cell's power plant, quietly converting nutrients into ATP and nothing more. That picture changed in 2001, when researchers screening surviving neurons from an Alzheimer's disease brain found a short, unexpected protein — one encoded not in the cell's nuclear DNA, but inside the mitochondria themselves.

That protein was named Humanin, and it turned out not to be alone. Fourteen years later, a second mitochondrial-encoded peptide, MOTS-c, was identified in a different region of the mitochondrial genome. Together with a handful of related molecules called SHLPs (small humanin-like peptides), they form a class now known as mitochondrial-derived peptides, or MDPs.

This article explains what MOTS-c and Humanin actually are, how each one works at the molecular level, what the published research says about their roles in metabolism and cellular aging, and where the current evidence is strong versus still preliminary.

Quick Answer: What Are Mitochondrial-Derived Peptides?

Where MOTS-c and Humanin Come From

Mitochondria carry their own small, circular genome — separate from the DNA in the cell nucleus. For decades, most of that mitochondrial DNA was assumed to code only for a small set of proteins involved directly in energy production. MDPs overturned that assumption by showing that regions long labeled "non-coding," including ribosomal RNA genes, actually contain short open reading frames (sORFs) capable of producing functional peptides.

Humanin: the first mitochondrial-derived peptide discovered

Humanin is a 24-amino-acid peptide encoded within the MT-RNR2 gene, inside the mitochondrial 16S rRNA region. It was identified in 2001 by researchers searching for factors that protected surviving neurons in Alzheimer's disease brain tissue from cell death. Since then, five to six related small humanin-like peptides (SHLP1-6) have been identified in the same genomic region.

MOTS-c: identified more than a decade later

MOTS-c (Mitochondrial Open reading frame of the Twelve S rRNA type-C) is a 16-amino-acid peptide encoded in the 12S rRNA gene of the mitochondrial genome. It was first characterized by USC researchers in 2015 for its striking effects on metabolic regulation and aging in mouse models.

How MOTS-c Works: Metabolism and Energy Sensing

MOTS-c functions as a stress-responsive messenger. Under conditions such as low glucose availability, oxidative stress, or metabolic strain, mitochondria increase MOTS-c production. The peptide then translocates into the nucleus, where it helps regulate the expression of genes involved in stress response and metabolic adaptation.

Mechanistically, MOTS-c is best characterized as an activator of AMP-activated protein kinase (AMPK) — the same cellular energy-sensing pathway targeted by several metabolic health strategies, including exercise itself. Preclinical research links MOTS-c to:

• Improved glucose uptake and insulin sensitivity in skeletal muscle in animal models
• Reduced diet-induced obesity and improved metabolic homeostasis in mice
• Age-related decline in circulating MOTS-c levels, observed in some human cohort studies
• Antioxidant defense support during metabolic stress

Human clinical research status for MOTS-c

As of 2026, MOTS-c has moved further into human clinical research than most other MDPs: a Phase 2a human trial is reportedly underway evaluating MOTS-c in prediabetes and insulin resistance, with endpoints including insulin sensitivity, glucose disposal, and exercise capacity. Results from this trial have not yet been published in peer-reviewed literature, so its clinical significance in humans remains unconfirmed pending publication.

How Humanin Works: Cell Survival and Neuroprotection

Humanin's defining research story is cytoprotection — helping cells survive stress rather than directly regulating energy metabolism. Several distinct molecular mechanisms have been characterized:

• IGFBP-3 binding: Humanin binds insulin-like growth factor-binding protein 3 (IGFBP-3), interfering with IGFBP-3's pro-apoptotic signaling and blocking a pathway that otherwise promotes cell death.
• BAX inhibition: Humanin binds the pro-apoptotic protein BAX, helping prevent mitochondrial membrane permeabilization — a key step in the classic apoptosis (programmed cell death) pathway.
• STAT3 and PI3K/Akt activation: Humanin activates the JAK2/STAT3 pathway linked to neuronal survival, and PI3K/Akt signaling that connects it to insulin-pathway biology.
• Receptor-mediated signaling: A trimeric cell-surface receptor complex involving CNTFR, WSX-1, and gp130 has been proposed as a high-affinity receptor for extracellular Humanin.

These mechanisms explain why Humanin research spans neurodegeneration (particularly Alzheimer's disease models), cardiovascular protection, age-related macular degeneration, and insulin-sensitizing effects, in addition to its original discovery context.

Human clinical research status for Humanin

Humanin's evidence base is currently the inverse of MOTS-c's: extensive and well-characterized mechanistic and animal-model research, but no completed, published human trials of exogenous Humanin administration for any indication. Circulating Humanin levels are being studied as a biomarker of mitochondrial health and biological age, which is a distinct research question from testing Humanin itself as an intervention.

MOTS-c vs. Humanin: Side-by-Side Comparison

Why Mitochondrial-Derived Peptides Matter for Aging Research

A 2026 review in the International Journal of Peptide Research and Therapeutics described MDPs as regulators of cellular stress resistance, metabolism, inflammation, and survival that interact with major aging pathways — including AMPK, mTOR, and the sirtuins. This positions MOTS-c, Humanin, and the SHLP family as a candidate class of "geroprotectors": molecules studied for their potential to help protect cells against age-related decline.

It's worth being precise about what this means in practice. Circulating levels of both MOTS-c and Humanin have been observed to decline with age in several human studies — an association, not proof that restoring these peptides reverses aging. The stronger, better-replicated evidence lies in the mechanistic pathways each peptide engages (AMPK for MOTS-c; IGFBP-3/BAX/STAT3 for Humanin), which are independently recognized as relevant to metabolic health and cell survival.

Common Mistakes When Interpreting MDP Research

• Treating MOTS-c and Humanin as interchangeable "anti-aging peptides" — they originate from different genes, engage different pathways, and are studied for different primary endpoints.
• Citing MOTS-c's Phase 2a trial as if results are already published — as of this writing, the trial is underway and outcomes have not appeared in peer-reviewed literature.
• Assuming Humanin's strong mechanistic data means it is clinically proven — no completed human trials of exogenous Humanin have been published, despite extensive cell and animal research.
• Confusing observational age-decline data (falling MOTS-c/Humanin levels with age) with interventional proof that raising these peptides slows aging.
• Overlooking that SHLPs 1-6 are part of the same MDP family but have a much smaller, less mature evidence base than MOTS-c or Humanin.

Key Takeaways

• Mitochondrial-derived peptides (MDPs) are small proteins encoded directly by mitochondrial DNA — a discovery that overturned the view of mitochondria as purely energy-producing organelles.
• MOTS-c (16 amino acids, discovered 2015) is primarily studied for metabolic regulation through AMPK activation, and has entered an early-phase human trial for prediabetes.
• Humanin (24 amino acids, discovered 2001) is primarily studied for cytoprotection and neuroprotection through IGFBP-3 binding, BAX inhibition, and STAT3 activation.
• Both peptides show robust preclinical and mechanistic evidence, but human clinical data remains limited: MOTS-c trial results are pending publication, and no completed human trials of exogenous Humanin exist as of 2026.
• Neither MOTS-c nor Humanin is FDA-approved for any indication; circulating-level research and biomarker studies should not be confused with proof that administering these peptides produces the same effects in humans.